Eltrombopag Tablets and Vitrakvi

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP. In 39 healthy adult subjects given eltrombopag 75 mg once daily for 4 days prior to coadministration with a single 10 mg dose of rosuvastatin on day 5, mean rosuvastatin peak plasma concentration (Cmax) increased by 103% and systemic exposure (AUC) by 55%. MANAGEMENT: Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy. References Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9 Kalliokoski A, Niemi M "Impact of OATP transporters on pharmacokinetics." Br J Pharmacol 158 (2009): 693-705 Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink." "Product Information. Promacta (eltrombopag)." GlaxoSmithKline, Research Triangle Park, NC. Cerner Multum, Inc. "Australian Product Information." O 0 View all 5 references

MONITOR: Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP. In 39 healthy adult subjects given eltrombopag 75 mg once daily for 4 days prior to coadministration with a single 10 mg dose of rosuvastatin on day 5, mean rosuvastatin peak plasma concentration (Cmax) increased by 103% and systemic exposure (AUC) by 55%.

MANAGEMENT: Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.

Eltrombopag Tablets

Generic Name: eltrombopag

Brand name: Promacta

Synonyms: Eltrombopag

What is Eltrombopag Tablets?

Vitrakvi

Generic Name: larotrectinib

Brand name: Vitrakvi

Synonyms: n.a.

What is Vitrakvi?